Kikuchi, Japan

Arisa Maeyashiki



Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2012-2014

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: Arisa Maeyashiki: Innovator in Recombinant Factor X Technology

Introduction

Arisa Maeyashiki is a prominent inventor based in Kikuchi, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of recombinant factor X. With a total of 3 patents to her name, her work has the potential to impact therapeutic applications significantly.

Latest Patents

One of her latest patents is titled "Recombinant factor X with no glycosylation and method for preparing the same." This invention provides a Factor X (FX) with high activity. The method described allows for the efficient preparation of a recombinant, two-chain FX by intervening glycosylation at an essential amino acid sequence. This innovative approach enables the expression of a recombinant FX without glycosylation, enhancing its therapeutic potential.

Career Highlights

Arisa has worked with notable organizations, including the Juridical Foundation the Chemo-Sero-Therapeutic Research Institute and the Chemo-Sero-Therapeutic Research Institute. Her experience in these institutions has allowed her to refine her expertise in biopharmaceutical research and development.

Collaborations

Throughout her career, Arisa has collaborated with esteemed colleagues such as Kenji Soejima and Takayuki Imamura. These partnerships have fostered a collaborative environment that encourages innovation and the advancement of scientific knowledge.

Conclusion

Arisa Maeyashiki's contributions to recombinant factor X technology exemplify her dedication to advancing biopharmaceutical research. Her innovative patents and collaborative efforts position her as a key figure in the field, paving the way for future advancements in therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…